BioCentury | Jan 10, 2020
Company News

Management tracks: COO, CMO depart as Solid restructures; plus Abeona, Millendo, Immuneering, Akouos, Kintai, Macrophage, Selexis, Prime

...officer, and Karoline Shair as SVP and general counsel. Molloy was chief commercial officer at Enzyvant Sciences GmbH...
BioCentury | Dec 7, 2019
Company News

Dec. 6 Company Quick Takes: Alexion rebuffs activist’s push for sale; plus UCB, Genmab, Enzyvant, Biohaven

...January (see “Genmab’s Blockbuster Darzalex surpasses $2B in Sales” ). CRL for Enzyvant’s regenerative therapy Enzyvant Sciences GmbH...
...Interleukin-17F BioCentury Staff bimekizumab (UCB4940) Darzalex, daratumumab (JNJ-54767414, humax-cd38) UCB S.A. Genmab A/S Biohaven Pharmaceutical Holding Co. Ltd. Johnson & Johnson Alexion Pharmaceuticals Inc. Enzyvant Sciences GmbH Interleukin-17A...
BioCentury | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

...a consultant to the company as well as CFO and head of corporate development at Enzyvant Sciences GmbH...
BioCentury | Oct 31, 2019
Company News

Roivant pockets $3B from Dainippon, reveals CF focus of fifth ‘vant’

...an array of genitourinary, women’s health and cancer products; pediatric and respiratory rare disease subsidiaries Enzyvant Sciences GmbH...
...Thursday; Urovant slipped $0.14 to $9.54. Elizabeth S. Eaton, Staff Writer Roivant Sciences Ltd. Myovant Sciences GmbH Urovant Sciences Ltd. Enzyvant Sciences GmbH Sumitomo...
BioCentury | Oct 18, 2019
Company News

Management tracks: Sirtex makes interim CEO permanent; plus Magenta, Pyxis, Stoke, Cadent, StemoniX, Enzyvant, Syapse and Stalicla

...joined as CFO. He was SVP and CFO of Biothera Pharmaceuticals Inc. Rare diseases company Enzyvant Sciences GmbH...
...Greenwood Genetic Center in South Carolina, a nonprofit with which Stalicla is collaborating. Jonathan Block, Associate Editor Enzyvant Sciences GmbH Stoke...
BioCentury | Sep 6, 2019
Company News

Sumitomo Dainippon to bolster pipeline via deal for women's health, urology, rare disease vants for $3B

...Sciences GmbH (NYSE:MYOV), Urovant Sciences Ltd. (NASDAQ:UROV), pediatric rare disease and respiratory rare disease subsidiaries Enzyvant Sciences GmbH...
...Assistant Editor Beova, vibegron (KRP-114V, MK-4618, RVT-901) Latuda, lurasidone (SM-13496) napabucasin (BBI608, BB608, BBI-608) Relumina (relugolix, TAK-385) Boston Biomedical Inc. Duke University Enzyvant Sciences GmbH J.P...
BioCentury | Jul 23, 2019
Company News

Management tracks: Epizyme, Disarm, Kaleido, Selecta and more

...partner at Atlas Venture, who has been serving as acting CEO. Shih was CEO of Enzyvant Sciences GmbH...
BioCentury | Jun 5, 2019
Company News

June 5 Company Quick Takes: Enzyvant's athymia candidate gets Priority review; plus Alnylam, Corbin and Institute Pasteur

...Priority Review for Enzyvant's RVT-802 Enzyvant Sciences GmbH (Basel, Switzerland) said FDA accepted and granted Priority Review to...
...synthase-1; USP15 - Ubiquitin specific peptidase 15 Elizabeth S. Eaton, Staff Writer givosiran (ALN-AS1) RVT-802 Alnylam Pharmaceuticals Inc. Corbin Therapeutics Inc. Enzyvant Sciences GmbH Institut...
BioCentury | Feb 21, 2019
Company News

Management tracks: Mirati, Verastem, RedHill

...a veteran of Prometheus Laboratories Inc., Covance Inc., MDS-Pharma Inc., Astra USA Inc. and BMS. Enzyvant Sciences GmbH...
BioCentury | Dec 13, 2018
Company News

Management tracks: Ambys, Foghorn

...position full time. He is a venture partner at Third Rock Ventures. Rare disease company Enzyvant Sciences GmbH...
Items per page:
1 - 10 of 19
BioCentury | Jan 10, 2020
Company News

Management tracks: COO, CMO depart as Solid restructures; plus Abeona, Millendo, Immuneering, Akouos, Kintai, Macrophage, Selexis, Prime

...officer, and Karoline Shair as SVP and general counsel. Molloy was chief commercial officer at Enzyvant Sciences GmbH...
BioCentury | Dec 7, 2019
Company News

Dec. 6 Company Quick Takes: Alexion rebuffs activist’s push for sale; plus UCB, Genmab, Enzyvant, Biohaven

...January (see “Genmab’s Blockbuster Darzalex surpasses $2B in Sales” ). CRL for Enzyvant’s regenerative therapy Enzyvant Sciences GmbH...
...Interleukin-17F BioCentury Staff bimekizumab (UCB4940) Darzalex, daratumumab (JNJ-54767414, humax-cd38) UCB S.A. Genmab A/S Biohaven Pharmaceutical Holding Co. Ltd. Johnson & Johnson Alexion Pharmaceuticals Inc. Enzyvant Sciences GmbH Interleukin-17A...
BioCentury | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

...a consultant to the company as well as CFO and head of corporate development at Enzyvant Sciences GmbH...
BioCentury | Oct 31, 2019
Company News

Roivant pockets $3B from Dainippon, reveals CF focus of fifth ‘vant’

...an array of genitourinary, women’s health and cancer products; pediatric and respiratory rare disease subsidiaries Enzyvant Sciences GmbH...
...Thursday; Urovant slipped $0.14 to $9.54. Elizabeth S. Eaton, Staff Writer Roivant Sciences Ltd. Myovant Sciences GmbH Urovant Sciences Ltd. Enzyvant Sciences GmbH Sumitomo...
BioCentury | Oct 18, 2019
Company News

Management tracks: Sirtex makes interim CEO permanent; plus Magenta, Pyxis, Stoke, Cadent, StemoniX, Enzyvant, Syapse and Stalicla

...joined as CFO. He was SVP and CFO of Biothera Pharmaceuticals Inc. Rare diseases company Enzyvant Sciences GmbH...
...Greenwood Genetic Center in South Carolina, a nonprofit with which Stalicla is collaborating. Jonathan Block, Associate Editor Enzyvant Sciences GmbH Stoke...
BioCentury | Sep 6, 2019
Company News

Sumitomo Dainippon to bolster pipeline via deal for women's health, urology, rare disease vants for $3B

...Sciences GmbH (NYSE:MYOV), Urovant Sciences Ltd. (NASDAQ:UROV), pediatric rare disease and respiratory rare disease subsidiaries Enzyvant Sciences GmbH...
...Assistant Editor Beova, vibegron (KRP-114V, MK-4618, RVT-901) Latuda, lurasidone (SM-13496) napabucasin (BBI608, BB608, BBI-608) Relumina (relugolix, TAK-385) Boston Biomedical Inc. Duke University Enzyvant Sciences GmbH J.P...
BioCentury | Jul 23, 2019
Company News

Management tracks: Epizyme, Disarm, Kaleido, Selecta and more

...partner at Atlas Venture, who has been serving as acting CEO. Shih was CEO of Enzyvant Sciences GmbH...
BioCentury | Jun 5, 2019
Company News

June 5 Company Quick Takes: Enzyvant's athymia candidate gets Priority review; plus Alnylam, Corbin and Institute Pasteur

...Priority Review for Enzyvant's RVT-802 Enzyvant Sciences GmbH (Basel, Switzerland) said FDA accepted and granted Priority Review to...
...synthase-1; USP15 - Ubiquitin specific peptidase 15 Elizabeth S. Eaton, Staff Writer givosiran (ALN-AS1) RVT-802 Alnylam Pharmaceuticals Inc. Corbin Therapeutics Inc. Enzyvant Sciences GmbH Institut...
BioCentury | Feb 21, 2019
Company News

Management tracks: Mirati, Verastem, RedHill

...a veteran of Prometheus Laboratories Inc., Covance Inc., MDS-Pharma Inc., Astra USA Inc. and BMS. Enzyvant Sciences GmbH...
BioCentury | Dec 13, 2018
Company News

Management tracks: Ambys, Foghorn

...position full time. He is a venture partner at Third Rock Ventures. Rare disease company Enzyvant Sciences GmbH...
Items per page:
1 - 10 of 19